Selecta Biosciences CEO and leadership

Selecta Biosciences, Inc. (NASDAQ: SELB), is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its selective immune tolerance technology (ImmTOR) platform. Passionate about improving patient’s lives.

Peter George Traber is an American pharmaceutical company executive. He is the former President and Chief Executive Officer for Galectin Therapeutics. He has been the president and chief executive officer of Baylor College of Medicine (BCM) and the John and Clara Whitmore Professor of Medicine. Traber succeeded Ralph Feigin to become the fourth president of BCM in March 2003, and was president until November 2008. Prior to joining Baylor, he served as Senior Vice President for Clinical Development & Medical Affairs and Chief Medical Officer at GlaxoSmithKline. Prior to that, Traber held positions as Chief Executive Officer of the University of Pennsylvania Health System and interim Dean, Chair of the Department of Internal Medicine for the University of Pennsylvania School of Medicine, Chief of Gastroenterology at the University of Pennsylvania School of Medicine, and faculty member at the University of Michigan School of Medicine. He received his undergraduate degree B.S. in Chemical Engineering at the University of Michigan in 1977, his M.D. from Wayne State Medical School in Michigan in 1981, and he trained as a gastroenterologist, after completing an internal medicine residency at Northwestern University School of Medicine in Chicago.

Selecta Biosciences, Inc. (NASDAQ: SELB), is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its selective immune tolerance technology (ImmTOR) platform. Passionate about improving patient’s lives.